Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade | Science
Second-line therapy with nivolumab plus ipilimumab for older patients with oesophageal squamous cell cancer (RAMONA): a multicentre, open-label phase 2 trial - The Lancet Healthy Longevity
The lung microenvironment: an important regulator of tumour growth and metastasis | Nature Reviews Cancer
FDA Approves Pembrolizumab for Additional Cancer Types | AACR Blog
Lung cancer - Wikipedia
Merck receives EC approval for Keytruda to treat relapsed Hodgkin Lymphoma - Pharmaceutical Technology
Zinc complex of 3,5-di-tert-butyl salicylate inhibits viability, migration, and invasion in triple-negative breast cancer cells | Scientific Reports
Immune checkpoint
Immunotherapy: combination regimens and new data on the significance of mutations - memoinOncology
Cancer immunotherapy using checkpoint blockade | Science
Frontiers | Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
Frontiers | Neuro-ophthalmic complications of immune checkpoint inhibitor therapy: Current status and future directions
Toll-like receptor 9 - Wikipedia
Frontiers | PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
Cancers | Free Full-Text | Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines
Cancer immunotherapy - Wikiwand
How to pronounce pembrolizumab | HowToPronounce.com
FDA Approves Merck's KEYTRUDA® (Pembrolizumab) for First-Line Treatment of Patients with Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer, First Single-Agent, Anti-PD-1 Therapy Approved for the First-Line Treatment of These Patients -
Genomic disparities between cancers in adolescent and young adults and in older adults | Nature Communications
Small-cell carcinoma - Wikipedia
eEML - Electronic Essential Medicines List
Pembrolizumab - Wikipedia
The future of immune checkpoint therapy | Science
Transitional cell carcinoma - Wikipedia
Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer
KEYTRUDA® (pembrolizumab) - Official Site
